Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 3
2(66.7%)
N/A
1(33.3%)
3Total
Phase 3(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials
NCT06810895Enrolling By Invitation

Evaluation of AK104 (Cadonilimab) Combined with Chemotherapy for Recurrent or Metastatic Small Cell Neuroendocrine Carcinoma of the Cervix

Role: lead

NCT01820858Phase 3Active Not Recruiting

The Efficacy and Safety of the Postoperative Adjuvant Treatment in Patients With High-risk Stage I Endometrial Carcinoma

Role: lead

NCT01820884Not ApplicableActive Not Recruiting

The Safety of Ovarian Preservation in Stage IA Endometrial Carcinoma

Role: lead

NCT05570331Unknown

Clinical Evaluation of HPV Integration Triage for Detection of Cervical Precancer in HPV-positive Women

Role: lead

NCT01823315Phase 3Unknown

Methotrexate Single-dose Treatment and Methotrexate/Actinomycin-D Single-dose Treatment in Low-Risk Gestational Trophoblastic Neoplasia

Role: lead

NCT01628757Unknown

Model Development and Prospective Validation to Predict the Response to Neoadjuvant Chemotherapy in Cervical Cancer

Role: lead

All 6 trials loaded